Spark Therapeutics, Inc.

Spark Therapeutics, Inc. is a biotechnology company founded in March 2013, focused on discovering and developing gene therapies for genetic diseases. With roots in the Children's Hospital of Philadelphia, the company aims to transform the lives of individuals affected by these conditions. In 2020, Spark Therapeutics became a subsidiary of Hoffmann-La Roche. The company utilizes a proprietary adeno-associated viral (AAV) vector platform to target inherited diseases by augmenting, replacing, or suppressing mutated genes. Spark Therapeutics invests significantly in research and development and is establishing a Gene Therapy Innovation Center in West Philadelphia for gene therapy manufacturing. Its product offerings include FDA-approved therapies like Voretigene neparvovec (Luxturna) for Leber's congenital amaurosis and Fidanacogene elaparvovec for hemophilia B, along with a robust pipeline of investigational treatments for various genetic disorders.